Navigation Links
FDA Reclassifies Certain Digital Mammography Devices
Date:11/4/2010

nvolve new technology that has not been widely used.

Class I and Class II devices pose lower risk and include adhesive bandages, wheelchairs, and many medical imaging technologies, such as MRI scanners and screen-film X-ray mammography. Class II devices require submission of a premarket notification, also known as a 510(k), to establish that the product is substantially equivalent to a device already on the market.

Along with the digital mammography reclassification, the FDA is releasing a "special controls" guidance for industry that describes what evidence will be needed to show substantial equivalence for these systems, including technical device specifications, images of standard test objects, and a sample set of patient images.

The FDA has approved five full field digital mammography systems since 2000, all were approved as Class III devices. About 70 percent of the mammography units in use are digital and 70 percent of certified U.S. mammography facilities have at least one digital unit, according to FDA reports from certified mammography facilities.

In May 2006, the FDA publicly discussed plans to reclassify FFD mammography systems from Class III to Class II at a Radiology Devices Panel meeting. After the positive response from the panel, the FDA published draft guidance for public comment in May 2008. The panel held another public meeting in November 2009 to discuss the comments received on the draft guidance.

Other than skin cancer, breast cancer is the most common type of cancer among women in the United States. An estimated 207,100 new cases of breast cancer in women will be diagnosed in 2010, according to the National Cancer Institute.

For more information:

Federal Register Notice


SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
2. Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases
3. St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors
4. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
5. St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse
6. CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
7. Christie Cookie Recalls Certain Lots of Peanut Butter Cookie Dough Due to Expanded Recall by Peanut Corporation of America
8. Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk
9. Trauma 411: Prolonged Surgery Should be Avoided in Certain Cases
10. FDA Orders Postmarket Surveillance Studies on Certain Spinal Systems
11. Unomedical Issues Worldwide Recall of Certain Manual Pulmonary Resuscitators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... SOUTH PLAINFIELD, N.J. , May 16, 2013 /PRNewswire/ ... a registration statement on Form S-1 with the U.S. ... initial public offering of its common stock. The number ... for the offering have not been determined. ... and Credit Suisse are acting as joint book-running managers ...
(Date:5/16/2013)... Mass. and SYDNEY , May ... - ASX: HIN), a leading innovator of less invasive, ... advanced heart failure, today announced that CEO Doug ... UBS Global Healthcare Conference at 11:00 a.m. EDT on Monday, ... 2013 at the Sheraton New York Hotel. A ...
(Date:5/16/2013)... , May 16, 2013 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the treatment ... Richard King , President and CEO, will present a ... Sheraton New York Hotel in New York ... 2013 at 9:30 a.m. ET/6:30 a.m. PT. The ...
Breaking Medicine Technology:PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 2AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 3
... N.Y., Dec. 1, 2011  Regeneron Pharmaceuticals, Inc. (Nasdaq: ... Company,s presentation at the 2011 Deutsche Bank BioFEST scheduled ... for 1:05 p.m. Eastern Time.  The session may be ... on the Investor Relations page.  An archived version of ...
... Ill., Dec. 1, 2011   Sysmex America, Inc., a global ... technology, today announces that the company has been named ... 100 Best Places to Work in Healthcare , ranking ... overall.  Results were based on company application and employee ...
Cached Medicine Technology:Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST 2Sysmex America Earns Spot on Top 100 Best Places to Work in Healthcare 2Sysmex America Earns Spot on Top 100 Best Places to Work in Healthcare 3
(Date:5/18/2013)... FRIDAY, May 17 (HealthDay News) -- It comes as little ... shows that college women are more likely to drink unhealthy ... men. Much of this difference is probably because ... basis is much lower for women than it is for ... there,s good reason for that difference. Women don,t metabolize alcohol ...
(Date:5/18/2013)... TheBeautyPlace.com answers important questions about the hairloss products ... result of stress, nutrient deficiency or wearing a favorite ... men suffer from male patterned baldness. , ... transplant surgery, but additionally carries a hair care product ... Professional Strength. Their product line is a five-step treatment ...
(Date:5/18/2013)... During Better Hearing and Speech Month, parents ... protections they have, including the right to bring a ... treatment or hearing aid device, attorney Ronald E. Johnson ... Association has used the month of May to raise ... as cochlear implants, which can improve the quality of ...
(Date:5/18/2013)... The “Sleep Apnea Diagnostic & Therapeutic Devices Market ... (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, ... the major market drivers, restraints, and opportunities in North ... Browse , 147 market data ... 318 pagesand in-depth TOC of “Sleep ...
(Date:5/18/2013)... Show And Go Training, the culmination of Eric ... that is all about is getting results in the fastest ... http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting an investigative review. , ... phase system” designed to make you faster, stronger, fitter and ... out in the gym. The training manual and exercise video ...
Breaking Medicine News(10 mins):Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2
... Health Information System via Remote Hosting Services to Improve ... , CINCINNATI, Dec. 9 Streamline ... announced that it will integrate its enterprise document ... of Massena Memorial Hospital, a leading quality health care ...
... , The following ... Recently there has been a ... our healthcare delivery system. We are told there are 46 ... are,calling for immediate government intervention with a nationalized healthcare,rescue plan ...
... Real-Time Linking to Lexi-Comp Drug Resources for Mutual Subscribers ... ... 2008 -- Institutions subscribing to DynaMed™ , or other ... able to seamlessly access real-time information from their Lexi-Comp ...
... over but Australian champion runner Craig Mottram had one more challenge to ... ... (PRWEB) December 9, 2008 -- The historic inaugural HBA Great Australian Run ... challenge to complete. , , , , ,Mottram, who was competing ...
... Cell Therapeutics, Inc.,(Nasdaq and MTA: CTIC) announced today ... ([90Y]-ibritumomab tiuxetan) were,presented at the American Society of Hematology ... In one presentation, the ... the use of single dose Zevalin as sole initial ...
... PLEASANTON, Calif., Dec. 8 Roche Molecular Diagnostics,announced today ... new,COBAS(R) AmpliPrep / COBAS(R) TaqMan(R) HBV Test v2.0, allowing ... Union. This highly sensitive test offers,Roche,s fully automated ... the quantitative detection of hepatitis B virus (HBV) DNA ...
Cached Medicine News:Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 2Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 3Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 4Health News:Streamline Health(R) Announces Massena Memorial Hospital to Implement Enterprise Document Workflow Solutions 5Health News:Average Americans Without Health Insurance Are Young and Healthy With Above Average Incomes 2Health News:EBSCO Publishing and Lexi-Comp Formalize Product Partnership to Enable Seamless Integration Between Products 2Health News:EBSCO Publishing and Lexi-Comp Formalize Product Partnership to Enable Seamless Integration Between Products 3Health News:EBSCO Publishing and Lexi-Comp Formalize Product Partnership to Enable Seamless Integration Between Products 4Health News:Mottram Honours His End of the HBA Great Australian Run challenge 2Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 2Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 3Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 4Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 5Health News:Improved Testing for Hepatitis B Virus From Roche 2Health News:Improved Testing for Hepatitis B Virus From Roche 3
Weitlaner-Locktite retractors, blunt, 11 cm total length....
Weitlaner Beckmann retractor, sharp prongs, SS....
Weitlaner retractor, blunt....
Daubenspeck sharp curette, 8....
Medicine Products: